Roche buys U.S. biotech Jecure in race for liver disease drugs
Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | Fatty Liver Disease (FLD) | Health | Liver | Liver Disease | Pfizer | Switzerland Health | Urology & Nephrology